Existing basic and clinical studies suggest that SGLT2-i may improve the prognosis of PH by reducing mPAP, pulmonary artery systolic and diastolic blood pressure, right ventricular systolic blood pressure, and reducing right ventricular hypertrophy and fibrosis (5–7). The gene discussed is SLC5A2; the disease is Right ventricular hypertrophy.